Keywords: algorx, licenses, novel, triptan, formulation, migraine, pharmaceuticals
AlgoRx licenses novel triptan formulation for migraine
Article | 17 February 2003
AlgoRx Pharmaceuticals of the USA has acquired rights to its thirdclinical-stage pipeline drug, ALGRX 2872, from a physician investigator. ALGRX 2872 consists ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
